Patents Examined by Daniel C Gamett
  • Human TNFRSF25 antibody
    Patent number: 10683358
    Abstract: Antibodies and antigen binding fragments that bind specifically to TNFRSF25 are provided herein. Methods for using the antibodies and antigen binding fragments to, for example, stimulate proliferation of human T cells (e.g., CD8+ T cells) and to treat cancer patients also are provided.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: June 16, 2020
    Assignee: Pelican Therapeutics, Inc.
    Inventor: Taylor H. Schreiber
  • Anti-TNFRSF25 antibodies
    Patent number: 10683359
    Abstract: Anti-TNFRSF25 antibodies and variants thereof, including those that bind to an epitope in the region of amino acids 48-71, are disclosed. Also contemplated are uses of the antibodies in research, diagnostic, and therapeutic applications.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: June 16, 2020
    Assignee: Pelican Therapeutics, Inc.
    Inventors: Taylor H. Schreiber, Jeff T. Hutchins
  • Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
    Patent number: 10669528
    Abstract: The methods and compositions described herein relate to producing, expanding, enriching, and/or maintaining hematopoietic stem cells ex vivo by treating the cells with an agent(s) that exhibits two or more activities selected from modulation of histone methylation; inhibition of TGF? signaling; inhibition of p38 signaling; activation of canonical Wnt signaling; and modulation of histone acetylation. In some embodiments, the technology described herein relates to transplantation of hematopoietic stem cells.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: June 2, 2020
    Assignees: CHILDREN'S MEDICAL CENTER CORPORATION, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Derrick J. Rossi, Wataru Ebina, Morag Stewart, Paula Gutierrez-Martinez, Lee L. Rubin, Lance Davidow
  • Methods and kits for monitoring membranous nephropathy
    Patent number: 10670597
    Abstract: An in vitro method can diagnose membranous nephropathy patient. The method includes detecting in a biological sample obtained from the patient one or more autoantibodies recognizing a Thrombospondin, Type I. Domain Containing 7A (THSD7A) protein.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: June 2, 2020
    Assignee: EUROIMMUN Medizinische Labordiagnostika AG
    Inventors: Gerard Lambeau, Nicola M. Tomas, Barbara Seitz-Polski, Rolf A. K. Stahl
  • Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer
    Patent number: 10660954
    Abstract: The novel synergistic combination of immune checkpoint blockade and hematopoietic stem cell transplantation and/or hematopoietic stem cell mobilization yield synergistic effects in disease therapy.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: May 26, 2020
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Duane Mitchell, Catherine Flores
  • Human T cell line assay for evaluating the immunologic identity of glatiramer acetate preparations
    Patent number: 10663457
    Abstract: The invention relates to the field of medicine. The invention provides methods for generating glatiramer-acetate-specific human T-cell lines, and assays that use these T-cell lines for demonstrating immunological identity between glatiramer acetate preparations. These assays allow sensitive and accurate comparison of glatiramer acetate preparations, and find utility as lot-release assays.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: May 26, 2020
    Assignee: Mylan Inc.
    Inventors: Jeffrey P. Smith, Peter E. Lipsky, Anne Lodge
  • Methods and materials for expanding antigen-specific T cells in culture
    Patent number: 10647961
    Abstract: This document provides methods and materials for expanding antigen-specific T cells (e.g., antigen-specific CD4+ T cells and/or antigen-specific CD8+ T cells) in culture. For example, methods and materials for performing a polyclonal stimulation step for a particular duration (e.g., from about 1 hour to about 48 hours) to increase the expansion of T cells having a desired antigen specificity are provided.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: May 12, 2020
    Assignees: Mayo Foundation for Medical Education and Research, University of Washington
    Inventors: Peter A. Cohen, Sandra J. Gendler, Latha B. Pathangey, Dustin B. McCurry, Jessica E. Gorman, Mary L. Disis
  • Restoring function of tumour acidified T cells
    Patent number: 10640806
    Abstract: Methods and compositions to restore function to acidified T cells are provided. The methods comprise administering urease to the T cells. Compositions comprise urease.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: May 5, 2020
    Assignee: Helix BioPharma Corp.
    Inventors: Wah Yau Wong, Baomin Tian, Kim Gaspar, Marni Diane Uger, Sven Rohmann, Heman Lap Man Chao
  • Method for preparing composition for promoting hair growth using Nanog-introduced mesenchymal stem cells derived from fetus in amniotic fluid
    Patent number: 10640541
    Abstract: The present invention relates to a culture solution of MSCs derived from a fetus in amniotic fluid, and more specifically, to a composition for promoting hair growth or preventing hair loss, which includes a culture solution of MSCs overexpressing a reprogramming factor Nanog and derived from a fetus in amniotic fluid as an active ingredient. In addition, the present invention relates to a method for preparing the composition, which includes culturing Nanog-introduced MSCs derived from a fetus in amniotic fluid in a conditioned medium and collecting the culture solution. The conditioned medium composition according to the present invention exhibits a hair growth promoting effect, and thus is able to be used as cosmetic and pharmaceutical compositions for promoting hair growth.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: May 5, 2020
    Assignee: Stemlab Inc.
    Inventors: Seung Kwon You, Eun Kyoung Jun, Jung Hyun Park, Won-Jin Yun, Da-Ryeon Son
  • Compositions and methods for cardiac tissue repair
    Patent number: 10632153
    Abstract: The invention features compositions comprising agents having cardiac protective activity isolated from epicardial progenitor cells and derivatives thereof, and methods for the use of such compositions.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: April 28, 2020
    Assignee: THE UNIVERSITY OF VERMONT AND STATE AGRICULTURE COLLEGE
    Inventor: Jeffrey Spees
  • B7-H1 fusion polypeptides for treating and preventing organ failure
    Patent number: 10632174
    Abstract: The present invention pertains to a fusion polypeptide for use in treating and/or preventing organ failure in a subject suffering from sepsis, said fusion polypeptide comprises at least (i) a first portion being a Fc portion of an immunoglobulin and (ii) a second portion comprising the extracellular portion of the human B7-H1 polypeptide or a variant thereof. Moreover, also encompassed by the invention is a polynucleotide encoding said fusion polypeptide for use in treating and/or preventing organ failure in a subject suffering from sepsis.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: April 28, 2020
    Assignee: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V
    Inventors: Andreas Von Knethen, Michael Parnham, Lisa Katharina Sha
  • Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics
    Patent number: 10613091
    Abstract: Methods of predicting responsiveness of a cancer in a subject to a cancer therapy including a VEGF targeting agent are provided herein. The methods include detecting the expression level of at least one biomarker selected from ANG-2, SDF-1 and VEGF-D in a sample from the subject and using the expression levels to determine whether the VEGF targeting agent will be effective to treat the cancer in the subject. The predictions may be used to develop treatment plans for the subjects. Methods of developing a prognosis for a subject with pancreatic cancer are also provided. These methods include determining the expression level of IGFBP-1, PDGF-AA and at least one of IL-6 or CRP in a sample from a subject with pancreatic cancer.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: April 7, 2020
    Assignee: Duke University
    Inventors: Andrew B. Nixon, Herbert I. Hurwitz, Herbert Pang, Mark D. Starr
  • Allogeneic autophagosome-enriched composition for the treatment of disease
    Patent number: 10597732
    Abstract: A method is presented for screening cells that produce allogeneic autophagosome enriched compositions able to induce expression of a selective marker on a subpopulation of peripheral blood mononuclear cells, the method comprising contacting a cell with a proteasome inhibitor, contacting the cell with a lysosome inhibitor, harvesting the resulting autophagosomes, determining a molecular signature of the harvested autophagosomes, and selecting cells that divert one or more Toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes. By screening for cells that divert one or more Toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes, enriched populations of autophagosomes may be generated which may illicit a specific immune response against numerous cancer types.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: March 24, 2020
    Assignees: UbiVac, LLC, Providence Health & Services-Oregon
    Inventors: Traci Hilton, Sandra Aung, Rieneke van de Ven, Christopher Paustian, Tarsem Moudgil, Christopher Dubay, Christopher Twitty, Hong-Ming Hu, Bernard A. Fox
  • Allogeneic autophagosome-enriched composition for the treatment of disease
    Patent number: 10597731
    Abstract: A method is presented for screening cells that produce allogeneic autophagosome enriched compositions able to induce expression of a selective marker on a subpopulation of peripheral blood mononuclear cells, the method comprising contacting a cell with a proteasome inhibitor, contacting the cell with a lysosome inhibitor, harvesting the resulting autophagosomes, determining a molecular signature of the harvested autophagosomes, and selecting cells that divert one or more Toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes. By screening for cells that divert one or more Toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes, enriched populations of autophagosomes may be generated which may illicit a specific immune response against numerous cancer types.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: March 24, 2020
    Assignees: UbiVac, LLC, Providence Health & Services-Oregon
    Inventors: Traci Hilton, Sandra Aung, Rieneke van de Ven, Christopher Paustian, Tarsem Moudgil, Christopher Dubay, Christopher Twitty, Hong-Ming Hu, Bernard A. Fox
  • Methods and kits for labeling, detection and isolation of Foxp3 regulatory T cells, isolated population of Foxp3 regulatory T cells thus obtained and uses thereof
    Patent number: 10591465
    Abstract: Disclosed is a method for labeling, detecting and/or isolating Foxp3+ Treg cells from a biological sample containing peripheral blood mononuclear cells (PBMC) or lymphocytes including the following steps of: (i) coupling the surface of PBMC or lymphocytes to a capture moiety which binds to the cell through a cell surface molecule and to interleukin-34 (IL34), (ii) culturing the lymphocytes under conditions wherein IL34 is secreted, released and specifically captured by the capture moiety, (iii) labeling the IL34 expressing lymphocytes with a label moiety, and (iv) optionally detecting and/or isolating the IL34 expressing lymphocytes which are Foxp3+ Treg cells. Also disclosed is an isolated population of Foxp3+ Treg cells obtainable by the method and uses thereof.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: March 17, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE NANTES, CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
    Inventors: Carole Guillonneau, Ignacio Anegon, Severine Bezie
  • Method of producing natural killer cells and composition for treating cancer
    Patent number: 10590385
    Abstract: A method for producing natural killer cells is disclosed. The method comprises isolating peripheral blood mononuclear cells (PBMCs) from a blood sample; isolating at least one of CD56+ cells and/or CD3?/CD56+ cells from the PBMCs; and co-culturing the at least one of CD56+ cells and/or CD3?/CD56+ cells with a combination of feeder cells in the presence of a cytokine. A composition for treating cancer is also disclosed. The composition comprises the CD56+ natural killer cells produced by the disclosed method and a cytokine.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: March 17, 2020
    Assignee: NKMAX CO., LTD.
    Inventors: Sang Woo Park, Yong Man Kim, Jae Seob Jung, Yong-Hee Rhee
  • CD133+ cells and method for expanding
    Patent number: 10590387
    Abstract: Provided herein are isolated CD133+ cells, such as human CD133+ cells, that have been expanded in culture and populations of isolated CD133+ cells that have been expanded in culture. The cells express transcription factors, growth factors, or a combination thereof, at altered levels compared to a naturally occurring CD133+ cell. Also provided are methods, including methods for expanding CD133+ cells and methods for using CD133+ cells.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: March 17, 2020
    Assignee: The Board of Regents of The University of Texas System
    Inventors: Larry Denner, Randall J. Urban, Yvonne Bodenburg
  • Method of inducing cardiomyocytes proliferation and treating heart diseases
    Patent number: 10589132
    Abstract: An Agrin peptide which induces proliferation of cardiomyocytes for treating a heart disease is provided.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: March 17, 2020
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Eldad Tzahor, Elad Bassat
  • Anti-AGE antibodies for treating inflammation and auto-immune disorders
    Patent number: 10584180
    Abstract: A composition for treating inflammation or auto-immune disorders comprises (i) an antibody that binds to an AGE-modified protein on a cell, and (ii) an anti-inflammation antibody. Furthermore, the antibody that binds to an AGE-modified protein on a cell is also effective to treat inflammation or auto-immune disorders alone.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: March 10, 2020
    Assignee: Siwa Corporation
    Inventor: Lewis S. Gruber
  • Compositions and methods for modulating an immune response
    Patent number: 10577586
    Abstract: The invention provides methods of modulating follicular regulatory T (TFR) cell-mediated immune responses, follicular helper T (TFH) cell-mediated immune responses or both, and the use of those methods in the treatment of diseases or conditions mediated by TFR or TFH cells. The invention also provides novel methods for identifying TFR and TFH cells in a population of cells. The invention also provides compositions comprising TFR cells that have enhanced suppressive activity as compared wild type TFR cells. The invention also provides compositions comprising T follicular regulatory (TFR) cells isolated from the peripheral blood of a subject wherein the composition is enriched for TFR cells. Methods of making and using the compositions of the invention to modulate an immune response are also provided.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: March 3, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: Arlene H. Sharpe, Peter T. Sage, Loise M. Francisco